The use of complementary alternative medicine in children and adolescents with autism spectrum disorder

Psychopharmacology Bulletin

Volumn 48, Issue 1, 2018, Pages 40-63

  DeFilippis, Melissa ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Alternative; Autism; Complementary; Symptoms; Treatment

Indexed keywords

ACETYLCYSTEINE; CARNOSINE; DIMETHYLGLYCINE; FOLINIC ACID; MELATONIN; OMEGA 3 FATTY ACID; OXYTOCIN; TETRAHYDROBIOPTERIN;

ALTERNATIVE MEDICINE; ARTICLE; AUTISM; BEHAVIORAL SCIENCE; CHILDHOOD AUTISM RATING SCALE; COGNITIVE BEHAVIORAL THERAPY; DIETARY INTAKE; DNA METHYLATION; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HEALTH PRACTITIONER; HUMAN; OXIDATIVE STRESS; ADOLESCENT; CHILD; PROCEDURES; PSYCHOLOGY;

ADOLESCENT; AUTISM SPECTRUM DISORDER; CHILD; COMPLEMENTARY THERAPIES; HUMANS;

EID: 85046772688     PISSN: 00485764     EISSN: 24722448     Source Type: Journal    
DOI: None     Document Type: Article

References (111)

1. Christensen DL, Baio J, Braun KV, et al. Prevalence and characteristics of autism spectrum disorder among children aged 8 years - Autism and Developmental Disabilities Monitoring Network, 11 sites, United States, 2012. MMWR Surveill Summ [serial online]. 2016;65(3):1-23.
2. Blumberg SJ, Bramlett MD, Kogan MD, et al. Changes in prevalence of parent-reported autism spectrum disorder in school-aged US Children: 2007 to 2011-2012. Natl Health Stat Report. 2013;65:1-11.
3. Black LI, Clarke TC, Barnes PM, Stussman BJ, Nahin RL. Use of complementary health approaches among children aged 4-17 years in the United States: National Health Interview Survey, 2007-2012. Natl Health Stat Report. 2015;78:1-18.
4. Akins RS, Krakowiak P, Angkustsiri K, Hertz-Picciotto I, Hansen RL. Utilization patterns of conventional and complementary/alternative treatments in children with autism spectrum disorders and developmental disabilities in a population-based study. J Dev Behav Pediatr. 2014;35(1):1-10.
5. Perrin JM, Coury DL, Hyman SL, Cole L, Reynolds AM, Clemons T. Complementary and alternative medicine use in a large pediatric autism sample. Pediatrics. 2012;130:S77-S82.
6. Christon LM, Mackintosh VH, Myers BJ. Use of complementary and alternative medicine (CAM) treatments by parents of children with autism spectrum disorders. Res Autism Spectr Disord. 2010;4: 249-259.
7. Hanson E, Kalish LA, Bunce E, et al. Use of complementary and alternative medicine among children diagnosed with autism spectrum disorder. J Autism Dev Disord. 2007;37:628-636.
8. Wong HHL, Smith RG. Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders. J Autism Dev Disord. 2006;36:901-909.
9. Levy SE, Frasso R, Colantonio S, et al. Shared decision making and treatment decisions for young children with autism spectrum disorder. Acad Pediatr. 2016;16(6):571-578.
10. Cortesi F, Giannotti F, Sebastiani T, Panunzi S, Valente D. Controlled-release melatonin, singly and combined with cognitive behavioral therapy, for persistent insomnia in children with autism spectrum disorders: a randomized placebo-controlled trial. J Sleep Res. 2012;21:700-709.
11. Wasdell MB, Jan JE, Bomben MM, et al. A randomized, placebo-controlled trial of controlled release melatonin treatment of delayed sleep phase syndrome and impaired sleep maintenance in children with neurodevelopmental disabilities. J Pineal Res. 2008;44:57-64.
12. Wright B, Sims D, Smart S, et al. Melatonin versus placebo in children with autism spectrum conditions and severe sleep problems not amenable to behavior management strategies: a randomized controlled crossover trial. J Autism Dev Disord. 2011;41:175-184.
13. Wirojanan J, Jacquemont S, Diaz R, et al. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5(2):145-150.
14. Garstang J, Wallis M. Randomized controlled trial of melatonin for children with autistic spectrum disorders and sleep problems. Child Care Health Dev. 2006;32(5):585-589.
15. Malow B, Adkins KW, McGrew SG, et al. Melatonin for sleep in children with autism: A controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord. 2012;42(8):1729-1737.
16. Bent S, Hendren RL, Zandi T, et al. Internet-based, randomized controlled trial of omega-3 fatty acids for hyperactivity in autism. J Am Acad Child Adolesc Psychiatry. 2014;53(6):658-666.
17. Aman MG, Sing NN, Stewart AW, Field CJ. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Retard. 1985;89:485-491.
18. Bent S, Bertoglio K, Ashwood P, Bostrom A, Hendren RL. A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. J Autism Dev Disord. 2011;41:545-554.
19. Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2007;61:551-553.
20. Mankad D, Dupuis A, Smile S, et al. A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. Mol Autism. 2015;6:18.
21. Cohen IL, Schmidt-Lackner S, Romanczyk R, Sudhalter V. The PDD behavior inventory: a rating scale for assessing response to intervention in children with pervasive developmental disorder. J Autism Dev Disord. 2003;33:31-45.
22. Reynolds CR, Kamphaus RW. BASC-2: Behavior Assessment System for Children: Manual. 2nd ed. San Antonio, TX: Pearson; 2006.
23. Ooi YP, Weng S-J, Jang LY, et al. Omega-3 fatty acids in the management of autism spectrum disorders: Findings from an open-label pilot study in Singapore. Eur J Clin Nutr. 2015;69:969-971.
24. Constantino JN, Gruber CP. Social Responsiveness Scale. Western Psychological Services: Los Angeles, USA, 2005.
25. Achenbach TM, Rescorla LA. Research Center for Children, Youth, and Families Manual for the ASEBA School-Age Forms and Prof iles. University of Vermont: Burlington, VT, USA, 2001.
26. Rossignol DA, Frye RE. A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Mol Psychiatry. 2012;17(4):389-401.
27. Bertoglio K, James SJ, Deprey L, Brule N, Hendren RL. Pilot study of the effect of methyl B12 treatment on behavioral and biomarker measures in children with autism. J Altern Complement Med. 2010;16(5):555-560.
28. Hendren RL, James SJ, Widjaja F, Lawton B, Rosenblatt A, Bent S. Randomized, placebo-controlled trial of methyl B12 for children with autism. J Child Adolesc Psychopharmacol. 2016;26(9):774-783.
29. Guy W. Assessment Manual for Psychopharmacology, Revised. Bethesda, MD. U.S. Department of Health, Education, and Welfare, 1976.
30. Frye RE, Slattery J, Delhey L, et al. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry. 2016;00:1-10.
31. Condouris K, Meyer E, Tager-Flusberg H. The relationship between standardized measures of language and measures of spontaneous speech in children with autism. Am J Speech Lang Pathol. 2003;12:349-358.
32. Volden J, Smith IM, Szatmari P, et al. Using the preschool language scale, fourth edition to characterize language in preschoolers with autism spectrum disorders. Am J Speech Lang Pathol. 2011;20:200-208.
33. Frye RE, Melnyk S, Fuchs G, et al. Effectiveness of methylcobalamin and folinic acid treatment on adaptive behavior in children with autistic disorder is related to glutathione redox status. Autism Res Treat. 2013;2013:609-705.
34. Sparrow S, Cicchetti D, Balla D. Vineland Adaptive Behavior Scales, P. Assessment. 2nd edition, Minneapolis, Minn, USA, 2005.
35. Sun C, Zou M, Zhao D, Xia W, Wu L. Efficacy of folic acid supplementation in autistic children participating in structured teaching: an open-label trial. Nutrients. 2016;8(6):337.
36. Park EY, Kim J. Factor structure of the childhood autism rating scale as per DSM-5. Pediatr Int. 2016;58(2):139-145.
37. Magiati I, Moss J, Yates R, Charman T, Howlin P. Is the Autism Treatment Evaluation Checklist a useful tool for monitoring progress in children with autism spectrum disorders? J Intellect Disabil Res. 2011;55:302-312.
38. De Giacomo A, Craig F, Cristella A, Terenzio V, Buttiglione M, Margari L. Can PEP-3 provide a cognitive profile in children with ASD? A comparison between the developmental ages of pep-3 and IQ of leiter-R. J Appl Res Intellect Disabil. 2015;29(6):566-573.
39. Chen KL, Chiang FM, Tseng MH, Fu CP, Hsieh CL. Responsiveness of the psychoeducational proilethird edition for children with autism spectrum disorders. J Autism Dev Disord. 2011;41:1658-1664.
40. Yatawara CJ, Einfeld SL, Hickie IB, Davenport TA, Guastella AJ. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Mol Psychiatry. 2016;21:1225-1231.
41. Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord. 2000;30:237-243.
42. Guastella AJ, Gray KM, Rinehart NJ, et al. The effects of a course of intranasal oxytocin on social behaviors in youth diagnosed with autism spectrum disorders: a randomized controlled trial. J Child Psychol Psychiatry. 2015;56(4):444-452.
43. Dadds MR, MacDonald E, Cauchi A, Williams K, Levy F, Brennan J. Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. J Autism Dev Disord. 2014;44:521-531.
44. Gresham FM, Elliot SN. Social skills rating scale. Circle Pines, MN: American Guidance Service, 1990.
45. Danfors T, von Knorring AL, Hartvig P, et al. Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study. J Clin Psychopharmacol. 2005;25(5):485-489.
46. Frye RE, DeLaTorre R, Taylor HB, et al. Metabolic effects of sapropterin treatment in autism spectrum disorder: A preliminary study. Transl Psychiatry. 2013. doi:10.1038/tp.2013.14.
47. Chez MG, Buchanan CP, Aimonovitch MC, et al. Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol. 2002; 17(11):833-837.
48. Gardner, Morrison F. Expressive One-Word Picture Vocabulary Test-Revised. Academic Therapy Publications, 1990.
49. Gardner, Morrison F. Receptive One-Word Picture Vocabulary Test. Academic therapy publications, 1985.
50. Gilliam, James E. Gilliam Autism Rating Scale: GARS. Pro-ed, 1995.
51. Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003;2:255-267.
52. Hardan AY, Fun LK, Libove RA, et al. A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry. 2012;71(11):956-961.
53. Wink LK, Adams R, Wang Z, et al. A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder. Mol Autism. 2016;7:26.
54. Ghanizadeh A, Moghimi-Sarani E. A randomized double blind placebo controlled clinical trial of N-acetylcysteine added to risperidone for treating autistic disorders. BMC Psychiatry. 2013;13:196.
55. Nikoo M, Radnia H, Farokhnia M, Mohammadi MR, Akhondzadeh S. N-Acetylcysteine as an adjunctive therapy to risperidone for treatment of irritability in autism: a randomized, double-blind, placebo-controlled clinical trial of efficacy and safety. Clin Neuropharmacol. 2015;38(1):11-17.
56. Kern JK, Miller VS, Cauller L, Kendall R, Mehta J, Dodd M. Effectiveness of N,N-Dimethylglycine in autism and pervasive developmental disorder. J Child Neurol. 2001;16(3):169-173.
57. Bolman WM, Richmond JA. A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder. J Autism Dev Disord. 1999;29(3):191-194.
58. Adams JB, Holloway C. Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med. 2004;10(6):1033-1039.
59. Adams JB, Audhya T, McDonough-Means S, et al. Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatrics. 2011;11:111.
60. Adams JB, Baral M, Geis E, et al. The severity of autism is associated with toxic metal body burden and red blood cell glutathione levels. J Toxicol. 2009. Article ID 532640.
61. Azzam HME, Sayyah H, Youssef S, et al. Autism and vitamin D: and intervention study. Middle East Current Psychiatry. 2015;22:9-14.
62. Saad K, Abdel-Rahman AA, Elserogy YM, et al. Vitamin D status in autism spectrum disorders and the efficacy of vitamin D supplementation in autistic children. Nutr Neurosci. 2016;19(8): 346-351.
63. Feng J, Shan L, Du L, et al. Clinical improvement following vitamin D3 supplementation in autism spectrum disorder. Nutr Neurosci. 2016. doi:10.1080/1028415X.2015.1123847. [Epub ahead of print].
64. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry. 1993;17:765-774.
65. Freeman BJ, Ritvo ER, Yokota A, Ritvo A. A scale for rating symptoms of patients with the syndrome of autism in real life settings. J Am Acad Child Adolesc Psychiatry. 1986;25:130-136.
66. Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database. 2005;4:CD003497.
67. Murza KA, Pavelko SL, Malani MD, Nye C. Vitamin B6-magnesium treatment for autism: the current status of the research. Magnes Res. 2010;23(2):115-117.
68. Stewart PA, Hyman SL, Schmidt BL, et al. Dietary supplementation in children with autism spectrum disorders: common, insufficient, and excessive. J Acad Nutr Diet. 2015;115(8):1237-1248.
69. Hasanzadeh E, Mohammadi MR, Ghanizadeh A, et al. A double-blind placebo controlled trial of ginkgo biloba added to risperidone in patients with autistic disorders. Child Psychiatry Hum Dev. 2012;43:674-682.
70. Adams JB, Johansen LJ, Powell LD, Quig D, Rubin RA. Gastrointestinal flora and gastrointestinal status in children with autism-comparisons to typical children and correlation with autism severity. BMC Gastroenterol. 2011;11:22.
71. Tomova A, Husarova V, Lakatosova S, et al. Gastrointestinal microbiota in children with autism in Slovakia. Physiol Behav. 2015;138:179-187.
72. Parracho HMRT, Gibson GR, Knott F, Bosscher D, Kleerebezem M, McCartney AL. A doubleblind, placebo-controlled, crossover-designed probiotic feeding study in children diagnosed with autistic spectrum disorders. Int J Probiotics Prebiotics. 2010;5:69-74.
73. Kaluzna-Czaplinska J, Blaszczyk S. The level of arabinitol in autistic children after probiotic therapy. Nutrition. 2012;28:124-126.
74. Saad K, Eltayeb AA, Mohamad IL, et al. A randomized, placebo-controlled trial of digestive enzymes in children with autism spectrum disorders. Clin Psychopharmacol Neurosci. 2015;13(2): 188-193.
75. Munasinghe SA, Oliff C, Finn J, Wray JA. Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial. J Autism Dev Disord. 2010;40:1131-1138.
76. Levy SE, Souders MC, Wray J, et al. Children with autistic spectrum disorders. I: Comparison of placebo and single dose of human synthetic secretin. Arch Dis Child. 2003;88:731-736.
77. Williams K, Wray JA, Wheeler DM. Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2012. Issue 4. Art. No: CD003495.
78. Hyman SL, Stewart PA, Foley J, et al. The gluten-free/casein-free diet: a double blind challenge trail in children with autism. J Autism Dev Disord. 2016;46(1):205-220.
79. Pusponegoro HD, Ismael S, Firmansyah A, Sastroasmoro S, Vandenplas Y. Gluten and casein supplementation does not increase symptoms in children with autism spectrum disorder. Acta Paediatr. 2015;104:e500-e505.
80. Elder JH, Shankar M, Shuster J, Theriaque D, Burns S, Sherrill L. The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord. 2006;36(3): 413-420.
81. Johnson CR, Handen BL, Zimmer M, Sacco K, Turner K. Effects of gluten free/casein free diet in young children with autism: a pilot study. J Dev Phys Disabil. 2011;23:213-225.
82. Whiteley P, Haracopos D, Knivsberg AM, et al. The ScanBrit randomized, controlled, single-blind study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders. Nutr Neurosci. 2010;13(2):87-100.
83. Knivsberg AM, Reichelt KL, Hoien T, Nodland M. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci. 2002;5(4):251-261.
84. Evangeliou A, Vlachonikolis I, Mihailidou H, et al. Application of a ketogenic diet in children with autistic behavior: pilot study. J Child Neurol. 2003;18(2):113-118.
85. Spilioti M, Evangeliou AE, Tramma D, et al. Evidence for treatable inborn errors of metabolism in a cohort of 187 Greek patients with autism spectrum disorder (ASD). Front Hum Neurosci. 2013;7:858.
86. Bashir S, Al-Ayadhi LY. Effect of camel milk on thymus and activation-regulated chemokine in autistic children: double-blind study. Pediatr Res. 2014;75(4):559-563.
87. Al-Ayadhi LY, Elamin NE. Camel milk as a potential therapy as an antioxidant in autism spectrum disorder (ASD). Evid Based Complement Alternat Med. 2013. 602834.
88. Al-Ayadhi LY, Halepoto DM, Al-Dress AM, Mitwali Y, Zainah R. Behavioral benefits of camel milk in subjects with autism spectrum disorder. J Coll Physicians Surg Pak. 2015;25(11):819-823.
89. Wong VCN, Chen WX, Liu WL. Randomized controlled trial of electro-acupuncture for autism spectrum disorder. Altern Med Rev. 2010;15(2):136-146.
90. Uniform Data System for Medical Rehabilitation (UDSMR). WeeFIM System SM. Clinical Guide: Version 5.01. Buffalo, NY: University at Buffalo 2000.
91. Haley SM, Coster WJ, Ludlow LH, Haltiwanger JT, Andrellos PJ. Pediatric Evaluation of Disability Inventory: Development, Standardization, and Administration Manual, Version 1.0. Boston MA: PEDI Research Group, 1992.
92. Roid GH, Miller LJ. Leiter International Performance Scale-Revised (Leiter-R). Wood Dale, IL; Stoelting Co: 1997.
93. Wong VCN, Sun JG. Randomized controlled trial of acupuncture versus sham acupuncture in autism spectrum disorder. J Altern Complement Med. 2010;16(5):545-553.
94. Griffiths R. The Abilities of Babies: A Study of Mental Measurements. London: University of London Press, 1954.
95. Reynell J. Reynell Language Developmental Scales. Windsor, UK: NFER-Nelson, 1976.
96. Lowe M, Costello AJ. Manual for Symbolic Play Test. Windsor, UK: NFER-Nelson, 1976.
97. Sampanthavivat M, Singkhwa W, Chaiyakul T, Karoonyawanich S, Ajpru H. Hyperbaric oxygen in the treatment of childhood autism: A randomized controlled trial. Diving Hyperb Med. 2012;42(3):128-133.
98. Rossignol DA, Rossignol LW, Smith S, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr. 2009;9:21.
99. Granpeesheh D, Tarbox J, Dixon DR, Wilke AE, Allen MS, Bradstreet JJ. Randomized trial of hyperbaric oxygen therapy for children with autism. Res Autism Spectr Disord. 2010;4:268-275.
100. Lord C, Rutter M, DiLavore PC, Risi S. Autism Diagnostic Observation Schedule. Los Angeles: Western Psychological Services: 1999.
101. Gupta S, Aggarwal S, Heads C. Brief report: dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord. 1996;26(4):439-452.
102. Plioplys AV. Intravenous immunoglobulin treatment of children with autism. J Child Neurol. 1998;13(2):79-82.
103. DelGiudice-Asch G, Simon L, Schmeidler J, Cunningham-Rundles C, Hollander E. Brief report: a pilot open clinical trial of intravenous immunoglobulin in childhood autism. J Autism Dev Disord. 1999;29(2):157-160.
104. Rierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17(4):241-251.
105. Green VA, Pituch KA, Itchon J, Choi A, O’Reilly M, Sigafoos J. Internet survey of treatments used by parents of children with autism. Res Dev Disabil. 2006;27:70-84.
106. Brown MJ, Willis T, Omalu B, Leiker R. Deaths resulting from hypocalcemia after administration of edentate disodium: 2003-2005. Pediatrics. 2006;118:534-536.
107. Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part A - medical results. BMC Clin Pharmacol. 2009;9:16.
108. Adams JB, Baral M, Geis E, et al. Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B behavioral results. BMC Clin Pharmacol. 2009;9:17.
109. Davis TN, O-Reilly M, Kang S, et al. Chelation treatment for autism spectrum disorders: a systematic review. Res Autism Spectr Disord. 2012;7:49-55.
110. James S, Stevenson SW, Silove N, Williams K. Chelation for autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2015. Issue 5. Art. No.: CD010766.
111. American Academy of Pediatrics. Committee on Children with Disabilities. Counseling families who choose complementary and alternative medicine for their child with chronic illness or disability. Pediatrics. 2001;107(3):598-601.